Resource Logo
NLM AIDSLINE

Thalidomide in the treatment of relapsed multiple myeloma.




 

Mayo Clin Proc. 2000 Sep;75(9):897-901. Unique Identifier : AIDSLINE

OBJECTIVE: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. PATIENTS AND METHODS: We studied 16 patients (median age, 64 years) who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. RESULTS: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. CONCLUSION: Thalidomide is an active agent in the treatment of patients with advanced myeloma.

JOURNAL ARTICLE Administration, Oral Aged Aged, 80 and over Angiogenesis Inhibitors/PHARMACOLOGY/*THERAPEUTIC USE Case Report Disease-Free Survival Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Human Male Middle Age Multiple Myeloma/CLASSIFICATION/*DRUG THERAPY/METABOLISM Muscle Proteins/BLOOD/URINE Recurrence Severity of Illness Index Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Thalidomide/PHARMACOLOGY/*THERAPEUTIC USE Treatment Failure



 




Information in this article was accurate in December 30, 2000. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.